Orphan Medicinal products

Orphan medicinal products are intended for the analysis, prevention or treatment of dangerous or very serious conditions that affect no more than 5 in 10,000 people in the European Union. Patients suffering from rare diseases deserve the same quality of treatment as other patients within the European Union. Given the small numbers of patients affected by rare diseases, the pharmaceutical industry has been unwilling in the past to invest in the research and development of medicinal products to treat them. The EU introduced new legislation in 2000 with the aim of providing incentives for the development of medicines for rare diseases (so-called orphan medicinal products).

  • Orphan designation
  • Medicines for rare diseases

Related Conference of Orphan Medicinal products

November 05-06, 2020

9th Asia Pacific STD and Infectious Diseases Congress

Tokyo, Japan
February 15-16, 2021

8th International Congress on Infectious Diseases

London, UK
May 10-11, 2021

4th Global Experts Meeting on Infectious Diseases

Singapore City, Singapore
September 06-07, 2021

11th World Congress on Rare Diseases and Orphan Drugs

Berlin, Germany

Orphan Medicinal products Conference Speakers

Recommended Sessions

Related Journals

Are you interested in